Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.

Lao C, Brown C, Obertová Z, Edlin R, Rouse P, Hodgson F, Holmes M, Gilling P, Lawrenson R.

Fam Pract. 2013 Dec;30(6):641-7. doi: 10.1093/fampra/cmt049. Epub 2013 Sep 21.

PMID:
24055993
2.

Screening for prostate cancer in New Zealand general practice.

Zuzana O, Ross L, Fraser H, Charis B, Alistair S, Leanne T, Michael H, Peter G.

J Med Screen. 2013 Mar;20(1):49-51. doi: 10.1177/0969141313485729. Epub 2013 May 13.

PMID:
23612467
3.

Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.

Obertová Z, Scott N, Brown C, Hodgson F, Stewart A, Holmes M, Lawrenson R.

BMC Fam Pract. 2014 Aug 26;15:145. doi: 10.1186/1471-2296-15-145.

5.

PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.

Brett J, Watson E, Hewitson P, Bukach C, Edwards A, Elwyn G, Austoker J.

BMC Fam Pract. 2005 Jun 9;6(1):24.

6.
7.

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.

Martin AJ, Lord SJ, Verry HE, Stockler MR, Emery JD.

Med J Aust. 2013 Jun 3;198(10):546-50. Erratum in: Med J Aust. 2014 Mar 3;200(4):205.

PMID:
23725269
8.

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer.

Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ.

Br J Cancer. 2009 Dec 1;101(11):1833-8. doi: 10.1038/sj.bjc.6605422. Epub 2009 Nov 10.

9.

The socioeconomic implications of prostate-specific antigen screening.

Benoit RM, Naslund MJ.

Urol Clin North Am. 1997 May;24(2):451-8. Review.

PMID:
9126243
10.

PSA testing in general practice.

Hodgson F, Obertová Z, Brown C, Lawrenson R.

J Prim Health Care. 2012 Sep 1;4(3):199-204.

PMID:
22946067
11.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

12.

An exploration of screening practices for prostate cancer and the associated community expenditure.

Perkins JJ, Sanson-Fisher RW, Clarke SJ, Youman P.

Br J Urol. 1998 Oct;82(4):524-9.

PMID:
9806181
13.

Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.

van Vugt HA, Roobol MJ, Venderbos LD, Joosten-van Zwanenburg E, Essink-Bot ML, Steyerberg EW, Bangma CH, Korfage IJ.

Eur J Cancer. 2010 Feb;46(3):669-77. doi: 10.1016/j.ejca.2009.11.022.

PMID:
20022239
14.

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.

Tawfik A.

Ont Health Technol Assess Ser. 2015 May 1;15(11):1-37. eCollection 2015. Review.

15.

Cost-effectiveness of Prostate Health Index for prostate cancer detection.

Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.

BJU Int. 2012 Aug;110(3):353-62. doi: 10.1111/j.1464-410X.2011.10751.x. Epub 2011 Nov 11.

16.

The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study.

Clements A, Watson E, Rai T, Bukach C, Shine B, Austoker J.

BMC Fam Pract. 2007 Jun 25;8:35.

17.

Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.

Obertová Z, Hodgson F, Scott-Jones J, Brown C, Lawrenson R.

J Rural Health. 2016 Winter;32(1):56-62. doi: 10.1111/jrh.12127. Epub 2015 Jul 14.

PMID:
26174590
18.

Prostate cancer screening trends in a large, integrated health care system.

Wallner L, Frencher S, Hsu JW, Loo R, Huang J, Nichol M, Jacobsen S.

Perm J. 2012 Summer;16(3):4-9.

19.

Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey.

Yasunaga H, Sugihara T, Imamura T.

Urology. 2011 Jun;77(6):1325-9. doi: 10.1016/j.urology.2011.02.025. Epub 2011 Apr 19.

PMID:
21507471
20.

Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.

Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.

Urol Int. 2007;79(4):336-44.

PMID:
18025853

Supplemental Content

Support Center